Pearl Therapeutics
Latest round
- Series D
Last raised
- Nov 2012
Total raised
- $109M
Investors
- 5
About Pearl Therapeutics
Pearl Therapeutics, Inc.Founded in 2006, Pearl Therapeutics is based in Redwood City, US, and specializes in developing inhaled medications for respiratory conditions.Pearl Therapeutics, Inc.Pearl Therapeutics, Inc.Pearl Therapeutics plans to leverage its recent acquisition by AstraZeneca to enhance its pipeline of inhalation therapies. The acquisition, finalized on June 27, 2013, includes an initial USD 560 mn payment with additional performance-based incentives. Future initiatives may involve expanding into new therapeutic areas and refining existing products to improve market reach.
Who invested in Pearl Therapeutics
5 investors across 5 rounds
See all investors in Pearl Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Pearl Therapeutics
Who invested in Pearl Therapeutics?
Pearl Therapeutics has 5 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pearl Therapeutics raised?
Pearl Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Pearl Therapeutics last raise money?
Pearl Therapeutics's most recent round on record is a Series D, in Nov 2012.
What does Pearl Therapeutics do?
Pearl Therapeutics is a pharmaceuticals company.
Where is Pearl Therapeutics headquartered?
Pearl Therapeutics is headquartered in Redwood City, US.
Which VCs invest in companies like Pearl Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Pearl Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Pearl Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.